Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02430532

BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) — INSPIRE  

Multiple Sclerosis, Secondary Progressive Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis

Clinical Trial Summary

The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with SPMS; The secondary objective of the study is to assess the effect of BG00012 compared with placebo on patient-reported outcomes, brain atrophy, and cognitive function.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02430532
Study type Interventional
Source Biogen
Contact
Status Terminated
Phase Phase 3
Start date May 2015
Completion date January 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT02273635 - Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Phase 1/Phase 2
Recruiting NCT05961644 - Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). Phase 2/Phase 3
Recruiting NCT05013463 - Hydroxychloroquine and Indapamide in SPMS Phase 2
Recruiting NCT04918225 - Motor Asymmetry in Progressive Multiple Sclerosis Patients
Completed NCT01982942 - Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Phase 2
Recruiting NCT05204459 - MS-ResearchBiomarkerS
Completed NCT00888277 - Bayer/Cognitive Assessments With Multiple Sclerosis Subjects N/A
Recruiting NCT05663853 - An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
Recruiting NCT05168384 - Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis Phase 1/Phase 2
Completed NCT02305264 - Imaging of Intracerebral Inflammation in MS N/A
Terminated NCT00468611 - Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Phase 3
Recruiting NCT05496881 - Exercise Effects in Multiple Sclerosis N/A
Completed NCT05357833 - Novel Imaging Markers in SPMS Early Phase 1
Completed NCT02506751 - Open-label Study of Liothyronine in MS Phase 1
Completed NCT00587691 - Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis Phase 1/Phase 2
Recruiting NCT04260711 - Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). N/A
Completed NCT02308137 - Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) Phase 2
Active, not recruiting NCT04993274 - Sensitivity of Motor Assessment in MS - a Prospective Cohort Study
Recruiting NCT05122559 - Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis Phase 2